Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Veeva Systems is the dominant cloud software provider for the global life sciences industry, serving pharmaceutical, biotech, and medical device companies with industry-specific CRM (Veeva Commercial Cloud) and clinical/regulatory content management solutions (Veeva Vault). The company maintains an estimated 80%+ market share in pharma CRM and has successfully expanded into adjacent verticals including clinical trials management, regulatory submissions, and quality management systems, creating a sticky multi-product platform with high switching costs.
Veeva operates a land-and-expand SaaS model with multi-year contracts (typically 3-5 years) and 95%+ renewal rates. Initial sales typically start with Commercial Cloud CRM, then expand to multiple Vault products as customers consolidate vendors. Pricing is based on user seats and data volume with annual escalators of 3-5%. The company benefits from extreme industry specialization - pre-built workflows for FDA submissions, EMA compliance, and pharma-specific data models create 18-24 month implementation advantages versus horizontal platforms like Salesforce or Microsoft. Gross margins of 74% reflect minimal infrastructure costs (runs on AWS) and high incremental margins on subscription revenue.
Subscription revenue growth rate and guidance (particularly Vault product family growth versus mature Commercial Cloud)
Net new customer additions in Development Cloud (clinical trials, regulatory) which signals expansion beyond core CRM
Calculated billings growth and remaining performance obligations (RPO) as leading indicators of future revenue
Operating margin expansion trajectory and free cash flow conversion rates above 40%
Competitive win/loss dynamics against Salesforce in CRM and emerging threats from IQVIA or Oracle in clinical systems
Salesforce re-entry into life sciences vertical with industry-specific solutions could erode Commercial Cloud market share, particularly if bundled with Health Cloud offerings
Regulatory changes reducing pharma profitability (drug pricing legislation, Medicare negotiation) could compress IT budgets and elongate sales cycles
Horizontal cloud platforms (Microsoft, Oracle, SAP) developing life sciences accelerators that commoditize Veeva's vertical specialization advantage
IQVIA (formerly Quintiles/IMS) leveraging clinical trial data assets and CRO relationships to bundle competitive software offerings
Oracle's acquisition strategy in life sciences (Cerner health records, clinical trial management systems) creating integrated competitor
Emerging point solutions in clinical trials (Medidata, acquired by Dassault) and regulatory (MasterControl) fragmenting the market
Minimal financial risk given fortress balance sheet with $2.1B cash, zero debt, and 40%+ FCF margins
Potential for large M&A that could dilute returns or integration risk, though company has historically been disciplined with tuck-in acquisitions only
low - Pharmaceutical and biotech R&D spending is highly inelastic and driven by patent cliffs, FDA approval pipelines, and long-term clinical trial commitments rather than GDP fluctuations. Veeva's mission-critical systems for regulatory compliance and commercial operations are last-budget-to-cut. However, biotech funding conditions (IPO markets, venture capital availability) can affect new customer formation in the 500-employee-and-below segment.
Moderate indirect sensitivity through biotech customer funding. Rising rates compress biotech valuations and reduce venture/IPO funding, which can slow new customer acquisition among smaller biotech firms (estimated 30-40% of customer base). However, large pharma customers (60-70% of revenue) are rate-insensitive. Veeva's own balance sheet has minimal debt and $2B+ cash, so direct financing impact is negligible. Higher rates may compress valuation multiples from historical 12-15x forward revenue to 8-10x range.
Minimal - Veeva has no meaningful debt ($0.01 D/E ratio) and customers are primarily investment-grade pharmaceutical companies or VC-backed biotechs with multi-year funding runways. Credit risk is limited to potential customer bankruptcies in biotech sector during funding droughts, but diversification across 1,300+ customers mitigates concentration risk.
growth - Veeva attracts quality growth investors seeking durable 15-20% revenue growth with expanding margins in a defensive end-market. The 74% gross margin, asset-light model, and recurring revenue appeal to SaaS-focused growth managers. Recent 36% drawdown reflects multiple compression from 15x forward revenue to 9-10x as interest rates rose, creating potential value entry point for growth-at-reasonable-price (GARP) investors. Not a dividend stock (no dividend paid) and limited appeal to deep value given still-premium valuation.
moderate - Historical beta around 0.9-1.1 with lower volatility than typical high-growth SaaS due to recurring revenue model and stable pharma end-market. However, stock exhibits momentum characteristics with sharp drawdowns during SaaS multiple compression cycles (2021-2022, 2025-2026). Quarterly earnings typically drive 5-10% single-day moves based on guidance revisions.
